USV sets up new plant at Vadodara

With an initial capital investment of around Rs 4000 million, the facility will provide employment to more than 350 people, despite being a very highly automated plant

Mumbai: Continuing with its journey towards global competitiveness, consolidating on its leadership in the diabetes segment and also leveraging on the Government’s surprise corporate tax rate cut, USV Private Limited has recently announced that it will immediately proceed with its investment on a new state-of-art formulation plant at Vadodara.

The recent announcement by the government has provided the much needed boost to the pharmaceutical manufacturing sector that requires investments to provide world class medicines to the population, at large. While the tax cut announced by the government will increase capital spending and generate employment in the pharmaceutical sector, these investments will also go a long way to improve sustainability and capacities in pharmaceutical manufacturing.

Managing Director, Mr Prashant Tewari, stated that, “The construction for the
new facility at Vadodara will start as early as October 2019, with an initial capital
investment of around Rs 4000 million. The facility will provide employment to
more than 350 people, despite being a very highly automated plant. The
company will manufacture its leading products in diabetes and hypertension
segments in this facility. The plant will supply to both the domestic and export
markets.”

The design of the plant will incorporate energy efficient systems, renewable
energy sources and water conservation features such as automated material
transfers, solar plants and rainwater harvesting. The facility will have well
designed programs around skill development and training of manpower.
The company is separately investing in a new Active Pharmaceutical Ingredient (API) plant at Ambernath.